Abbott India

    ABBOTINDIA
    Pharma
    ₹25,470.00
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹54,122 Cr

    P/E
    32.75
    Day range
    ₹25,400.00 – ₹25,950.00
    52-week range
    ₹24,650.00 – ₹30,655.00
    Volume
    6,603
    Open
    ₹25,865.00
    Prev close
    ₹25,815.00

    Latest results · Q2 FY27(consolidated)Revenue ₹1,951 Cr+11.0%Profit ₹453 Cr+9.2%Margin 23.2%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 67 / 100

    Factor percentiles

    Value41
    Quality87
    Momentum41
    Low volatility97

    Derived metrics

    Earn. yield
    3.1%
    Graham no.
    ₹5,820.55
    vs Graham
    -77.1%
    ROE ÷ P/B
    2.6%
    12-1 mom.
    -11.3%
    Return / vol
    -0.66
    Magic Formula
    #93
    Piotroski
    5/5
    FCF yield
    2.4%
    PEG
    3.56

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Abbott IndiaABBOTINDIA₹54,122 Cr32.7513.1534.5%45.0%29.0%0.04+11.0%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 1d ago

    Headlines about Abbott India from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    34.1
    EPS (TTM)
    ₹777.85
    ROE (FY26)
    34.5%
    ROCE (latest year)
    45%
    Dividend yield
    1.98%

    Moving averages (NSE)

    20-day
    ₹25,982.5
    Price below
    50-day
    ₹26,150.8
    Price below
    200-day
    ₹26,563.68
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +9.0%
    Profit 3Y CAGR
    +17.8%
    Revenue YoY (Sep 2026 (S))
    +11.0%
    Profit YoY (Sep 2026 (S))
    +9.2%
    Operating margin
    29.0%
    Net margin
    23.2%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023 (S)Jun 2024 (S)Dec 2024 (S)Jun 2025 (S)Dec 2025 (S)Sep 2026 (S)0%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2018 (S)Mar 2020 (S)Mar 2022 (S)Mar 2024 (S)Mar 2026 (S)-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2019 (S)Mar 2021 (S)Mar 2023 (S)Mar 2025 (S)Sep 2026 (S)0x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹200₹400₹600

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023 (S)Mar 2024 (S)Jun 2024 (S)Sep 2024 (S)Dec 2024 (S)Mar 2025 (S)Jun 2025 (S)Sep 2025 (S)Dec 2025 (S)Mar 2026 (S)Jun 2026 (S)Sep 2026 (S)
    Sales1,4371,4391,5581,6331,6141,6051,7381,7571,7241,7101,8141,951
    Expenses1,0491,1091,1671,1941,1781,1761,2931,2551,2611,2291,2911,383
    Operating Profit388330391439436429446502463481522568
    OPM %27%23%25%27%27%27%26%29%27%28%29%29%
    Other Income568167607276737070767568
    Interest333224685666
    Depreciation181818181818191919192019
    Profit before tax422390437479488483493546509531572610
    Tax %26%26%25%25%26%24%26%24%26%26%25%26%
    Net Profit311287328359361367366415376395429453
    EPS in Rs₹146.35₹135.09₹154.36₹168.76₹169.78₹172.73₹172.18₹195.43₹176.93₹185.86₹201.66₹213.40

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days19

    -2 days since Mar 2021 (S)

    Inventory Days94

    -16 days since Mar 2021 (S)

    Days Payable109

    -7 days since Mar 2021 (S)

    Cash Conversion Cycle3

    -11 days since Mar 2021 (S)

    Working Capital Days2

    -2 days since Mar 2021 (S)

    Strengths, risks & growth

    Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. [1] It was established in 1944. [2]

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter74.99%74.99%74.99%74.99%0.00 pp
    FII0.19%0.27%0.38%0.40%+0.02 pp
    DII9.00%8.93%8.77%8.99%+0.22 pp
    Public15.83%15.81%15.85%15.62%-0.23 pp

    Analysts & fund holdings

    67%
    67% recommend buy
    9 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E32.7 vs 45.2
    Sector P/B6.05
    Beta0.05

    Who holds the shares, quarter by quarter

    Mutual funds 7.55% (+0.11 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters75.0%
    • Foreign institutions0.4%
    • Mutual funds7.5%
    • Insurance1.3%
    • Other domestic institutions0.2%
    • Retail13.1%
    • Others2.5%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    SBI Large & Midcap Fund1.45%1.98%-0.04 pp
    Nippon India Multi Cap Fund0.75%0.79%+0.16 pp
    Axis Midcap Fund0.63%1.05%-0.27 pp
    Canara Rob Large and Mid Cap Fund0.62%1.39%-0.02 pp
    Nippon India Pharma Fund0.36%2.22%-0.03 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    20.7%
    Downside volatility
    18.7%
    Worst 5% of days
    2.0%
    Average of that tail
    2.6%
    Max drawdown (1Y)
    19.2%
    Below its peak
    17.8%

    Against the market

    Beta vs Nifty 50
    0.23
    Correlation
    0.15
    Relative strength (3M)
    -9.2%
    ATR (14)
    2.5%

    Return

    Return 1M
    -2.7%
    Return 3M
    -5.3%
    Return 6M
    -8.8%
    Return 1Y
    -13.7%
    vs 200-day average
    -4.1%

    Momentum

    RSI (14)
    43.1
    MACD histogram
    -44.36
    Stochastic %K
    3.4
    ADX (14)
    15.0
    +DI / −DI
    16.6 / 23.5
    Money flow index
    45.7

    Participation

    Delivery (20d avg)
    56.0%
    vs its 60-day baseline
    +1.3 pts
    Volume vs 20-day
    -0.3σ
    Close vs day's VWAP
    -0.6%
    52-week position
    7 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    5 of 5 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — not testableneeds total income and expenses a year apart
    • Asset turnover improving — passed
    Free cash flow
    ₹1,278 Cr
    FCF yield
    2.4%
    Net debt
    -₹683 Cr
    Net debt / equity
    -0.16
    EV / sales
    7.42
    PEG
    3.56
    Revenue CAGR
    11.0%
    Profit CAGR
    9.2%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹525.00

      Dividend - Rs 525 Per Share & Special Dividend Rs 131 Per Share

      24 Jul 2026
      ex-date
    • dividend
      ₹475.00

      Dividend - Rs 475 Per Share

      25 Jul 2025
      ex-date
    • dividend
      ₹410.00

      Dividend - Rs 410 Per Share

      19 Jul 2024
      ex-date
    • dividend
      ₹180.00

      Dividend - Rs 180 Per Share/ Special Dividend Rs 145 Per Share

      21 Jul 2023
      ex-date
    • dividend
      ₹145.00

      Annual General Meeting/Dividend - Rs 145 Per Share/Special Dividend- 130 Per Share

      2 Aug 2022
      ex-date
    • dividend
      ₹120.00

      Annual General Meeting/Dividend - Rs 120 Per Share Special Dividend 155 Per Share

      19 Jul 2021
      ex-date
    • dividend
      ₹107.00

      Annual General Meeting/Dividend - Rs 107 Per Share And Special Dividend - Rs 143 Per Share

      28 Aug 2020
      ex-date
    • dividend
      ₹50.00

      Annual General Meeting/ Final Dividend - Rs 50 Per Share/ Special Dividend - Rs 15 Per Share

      13 Aug 2019
      ex-date
    • dividend
      ₹50.00

      Annual General Meeting / Final Dividend- Rs 50 Per Share / Special Dividend- Rs 5 Per Share

      10 Jul 2018
      ex-date
    • dividend
      ₹40.00

      Annual General Meeting/Dividend Rs 40/- Per Share

      10 Jul 2017
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting/Divided - Rs 35/- Per Share

      8 Jul 2016
      ex-date
    • dividend
      ₹31.00

      Annual General Meeting/Dividend - Rs 31/- Per Share

      22 Jul 2015
      ex-date
    • dividend
      ₹23.00

      Annual General Meeting / Final Dividend - Rs 23/- Per Share

      23 Jul 2014
      ex-date
    • dividend
      ₹17.00

      Annual General Meeting And Dividend Rs.17 Per Share

      16 Apr 2013
      ex-date
    • dividend
      ₹17.00

      Annual General Meeting And Dividend Rs.17/- Per Share

      4 May 2012
      ex-date
    • dividend
      ₹17.00

      Annual General Meeting / Final Dividend - Rs.17/- Per Share

      19 Apr 2011
      ex-date
    • other
      Not available — not reported in this filing

      Agm/Div-Rs.17/- Per Share

      3 Mar 2010
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities.

    Insider Trading / SAST
    Closure of Trading Window

    Closure of Trading Window for declaration of Unaudited Financial Results of the Company for the quarter ending September 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

    Resignation of Company Secretary and Compliance Officer of the Company.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting Results along with Consolidated Scrutinizer's Report for the 82nd Annual General Meeting held on August 13, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of 82nd Annual General Meeting of the Company.

    Result
    Unaudited Financial Results For The Quarter Ended June 30, 2026.

    Unaudited financial results for the quarter ended June 30, 2026.

    Board Meeting
    Board Meeting Outcome for Outcome Of Board Meeting

    Outcome of Board Meeting

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026.

    Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement for Eighty-second Annual General Meeting, E-voting facility and Dividend.

    Company Update
    Communication Providing The Weblink Including Path Of Annual Report.

    Communication providing the weblink including path of Annual Report.

    Others
    Business Responsibility and Sustainability Reporting (BRSR)

    Submission of Business Responsibility and Sustainability Report for the Financial Year 2025-26.

    AGM/EGMPrice-sensitive
    Annual General Meeting On August 13, 2026.

    Notice of the 82nd Annual General Meeting of the Company to be held on August 13, 2026.

    Filed with BSE (scrip 500488); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    • Buyback

      Abbott India Limited

      16 Jul 2008
      Read on SEBI
    • Buyback - Buyback

      Abbott India Limited - Buyback

      6 Mar 2007
      Read on SEBI
    • Buyback - Form of Acceptance

      Abbott India Limited - Form of Acceptance

      6 Mar 2007
      Read on SEBI
    • Open offer

      Abbott India Limited

      11 Oct 2006
      Read on SEBI

    Regulatory orders

    • Order

      In the matter of Proposed Acquisition of voting rights of Abbott India Limited

      17 Jun 2008
      Read on SEBI
    • Order

      Order against M/s Abbott India Ltd

      25 Jan 2007
      Read on SEBI

    Documents

    Documents open at BSE or the rating agency that issued them.

    FAQ

    Abbott India: common questions

    Answered from the figures on this page.

    Abbott India last traded at ₹25,470.00 (NSE, as of 18 Nov 2026). The last session moved it down 1.34%.

    Abbott India is valued at about ₹54,122 crore (NSE, as of 18 Nov 2026).

    Abbott India trades at a price-to-earnings ratio of 32.75 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Abbott India has traded between ₹24,650.00 and ₹30,655.00 over the past 52 weeks, to 18 Nov 2026. It is currently 14% of the way up that range.

    Abbott India (ABBOTINDIA) is classified under Pharma on this site's screener.